Try a new search

Format these results:

Searched for:

in-biosketch:true

person:liccif01

Total Results:

134


Depot leuprolide acetate does not adversely affect oocyte donor stimulation [Meeting Abstract]

Flisser, E; Levine, BA; Krey, LC; Licciardi, F
ISI:000241038502013
ISSN: 0015-0282
CID: 70640

Subchorionic hematoma associated with heterotopic pregnancy following in vitro fertilization: a case report [Case Report]

Flisser, Eric; Licciardi, Frederick
BACKGROUND: After treatment for infertility using in vitro fertilization (IVF)-embryo transfer, a high index of suspicion must be maintained for early diagnosis and treatment of concurrent ectopic pregnancy; however, the likelihood of a positive outcome for the intrauterine pregnancy remains uncertain. CASE: A subchorionic hematoma threatening an intrauterine gestation noted concurrently with ultrasound diagnosis of a heterotopic IVF pregnancy resolved following laparoscopic salpingectomy. CONCLUSION: Although symptomatic subchorionic hematoma may be associated with an increase in the rate of spontaneous miscarriage for a singleton pregnancy, it may not present a similar risk in the presence of a concurrent heterotopic gestation
PMID: 16846092
ISSN: 0024-7758
CID: 67928

One at a time [Editorial]

Flisser, Eric; Licciardi, Frederick
Review of abstracts presented at the 2004 Annual Meeting of the American Society for Reproductive Medicine clearly demonstrate that good prognosis patients should be given the option of a single embryo transfer
PMID: 16500318
ISSN: 1556-5653
CID: 63412

Influence of endometrial thickness (ET) less than 7 millimeters on donor oocyte recipient outcomes [Meeting Abstract]

Conway, D. A.; Flisser, E.; Krey, L. C.; Licciardi, F. L.
ISI:000241038500164
ISSN: 0015-0282
CID: 2305462

Embryo and oocyte cryopreservation in female cancer patients: Does malignancy affect stimulation outcome? [Meeting Abstract]

Knopman, J. M.; Talebian, S.; Noyes, N.; Grifo, J. A.; Krey, L. C.; Licciardi, F.
ISI:000241038501250
ISSN: 0015-0282
CID: 2305472

Combined oral contraceptives in women with systemic lupus erythematosus

Petri, Michelle; Kim, Mimi Y; Kalunian, Kenneth C; Grossman, Jennifer; Hahn, Bevra H; Sammaritano, Lisa R; Lockshin, Michael; Merrill, Joan T; Belmont, H Michael; Askanase, Anca D; McCune, W Joseph; Hearth-Holmes, Michelene; Dooley, Mary Anne; Von Feldt, Joan; Friedman, Alan; Tan, Mark; Davis, John; Cronin, Mary; Diamond, Betty; Mackay, Meggan; Sigler, Lisa; Fillius, Michael; Rupel, Ann; Licciardi, Frederick; Buyon, Jill P
BACKGROUND: Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the effect of oral contraceptives on lupus activity in premenopausal women with systemic lupus erythematosus. METHODS: A total of 183 women with inactive (76 percent) or stable active (24 percent) systemic lupus erythematosus at 15 U.S. sites were randomly assigned to receive either oral contraceptives (triphasic ethinyl estradiol at a dose of 35 microg plus norethindrone at a dose of 0.5 to 1 mg for 12 cycles of 28 days each; 91 women) or placebo (92 women) and were evaluated at months 1, 2, 3, 6, 9, and 12. Subjects were excluded if they had moderate or high levels of anticardiolipin antibodies, lupus anticoagulant, or a history of thrombosis. RESULTS: The primary end point, a severe lupus flare, occurred in 7 of 91 subjects receiving oral contraceptives (7.7 percent) as compared with 7 of 92 subjects receiving placebo (7.6 percent). The 12-month rates of severe flare were similar: 0.084 for the group receiving oral contraceptives and 0.087 for the placebo group (P=0.95; upper limit of the one-sided 95 percent confidence interval for this difference, 0.069, which is within the prespecified 9 percent margin for noninferiority). Rates of mild or moderate flares were 1.40 flares per person-year for subjects receiving oral contraceptives and 1.44 flares per person-year for subjects receiving placebo (relative risk, 0.98; P=0.86). In the group that was randomized to receive oral contraceptives, there was one deep venous thrombosis and one clotted graft; in the placebo group, there was one deep venous thrombosis, one ocular thrombosis, one superficial thrombophlebitis, and one death (after cessation of the trial). CONCLUSIONS: Our study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable
PMID: 16354891
ISSN: 1533-4406
CID: 62351

Reducing the risk of multiple gestations with ovulation induction and intrauterine insemination: One center's experience [Meeting Abstract]

Fino, E; Keegan, DA; Noyes, N; Licciardi, F; Berkeley, AS; Grifo, JA
ISI:000232114601188
ISSN: 0015-0282
CID: 59570

The effect of media and protein supplements as well as day of embryo transfer (ET) on monozygotic twinning (MZT) rates [Meeting Abstract]

Lee, HL; Adler, A; Labella, P; McCaffrey, C; Licciardi, F; Krey, LC
ISI:000232114601354
ISSN: 0015-0282
CID: 59574

Surgical correction of uterine septum improves fertility and pregnancy outcome [Meeting Abstract]

Fino, E; Noyes, N; Keegan, DA; Grifo, JA; Berkeley, AS; Licciardi, F
ISI:000232114601609
ISSN: 0015-0282
CID: 59580

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

Buyon, Jill P; Petri, Michelle A; Kim, Mimi Y; Kalunian, Kenneth C; Grossman, Jennifer; Hahn, Bevra H; Merrill, Joan T; Sammaritano, Lisa; Lockshin, Michael; Alarcon, Graciela S; Manzi, Susan; Belmont, H Michael; Askanase, Anca D; Sigler, Lisa; Dooley, Mary Anne; Von Feldt, Joan; McCune, W Joseph; Friedman, Alan; Wachs, Jane; Cronin, Mary; Hearth-Holmes, Michelene; Tan, Mark; Licciardi, Frederick
BACKGROUND: There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE). OBJECTIVE: To evaluate the effect of hormone replacement therapy (HRT) on disease activity in postmenopausal women with SLE. DESIGN: Randomized, double-blind, placebo-controlled noninferiority trial conducted from March 1996 to June 2002. SETTING: 16 university-affiliated rheumatology clinics or practices in 11 U.S. states. PATIENTS: 351 menopausal patients (mean age, 50 years) with inactive (81.5%) or stable-active (18.5%) SLE. Interventions: 12 months of treatment with active drug (0.625 mg of conjugated estrogen daily, plus 5 mg of medroxyprogesterone for 12 days per month) or placebo. The 12-month follow-up rate was 82% for the HRT group and 87% for the placebo group. MEASUREMENTS: The primary end point was occurrence of a severe flare as defined by Safety of Estrogens in Lupus Erythematosus, National Assessment-Systemic Lupus Erythematosus Disease Activity Index composite. RESULTS: Severe flare was rare in both treatment groups: The 12-month severe flare rate was 0.081 for the HRT group and 0.049 for the placebo group, yielding an estimated difference of 0.033 (P = 0.23). The upper limit of the 1-sided 95% CI for the treatment difference was 0.078, within the prespecified margin of 9% for noninferiority. Mild to moderate flares were significantly increased in the HRT group: 1.14 flares/person-year for HRT and 0.86 flare/person-year for placebo (relative risk, 1.34; P = 0.01). The probability of any type of flare by 12 months was 0.64 for the HRT group and 0.51 for the placebo group (P = 0.01). In the HRT group, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an arteriovenous graft; in the placebo group, 1 patient developed deep venous thrombosis. LIMITATIONS: Findings are not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or previous thrombosis. CONCLUSIONS: Adding a short course of HRT is associated with a small risk for increasing the natural flare rate of lupus. Most of these flares are mild to moderate. The benefits of HRT can be balanced against the risk for flare because HRT did not significantly increase the risk for severe flare compared with placebo
PMID: 15968009
ISSN: 1539-3704
CID: 55990